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Abstract
Purpose: Mitochondrial disease is the most common neuromuscular disease and has a profound impact upon daily life,
disease and longevity. Exercise therapy has been shown to improve mitochondrial function in patients with mitochondrial
disease. However, no information exists about the level of habitual physical activity of people with mitochondrial disease
and its relationship with clinical phenotype.
Methods: Habitual physical activity, genotype and clinical presentations were assessed in 100 patients with mitochondrial
disease. Comparisons were made with a control group individually matched by age, gender and BMI.
Results: Patients with mitochondrial disease had significantly lower levels of physical activity in comparison to matched
people without mitochondrial disease (steps/day; 688363944 vs. 992464088, p=0.001). 78% of the mitochondrial disease
cohort did not achieve 10,000 steps per day and 48%were classified as overweight or obese. Mitochondrial disease was
associated with less breaks in sedentary activity (Sedentary to Active Transitions, % per day; 1360.03 vs. 1460.03, p=0.001)
and an increase in sedentary bout duration (bout lengths / fraction of total sedentary time; 0.20660.044 vs. 0.18760.026,
p=0.001). After adjusting for covariates, higher physical activity was moderately associated with lower clinical disease
burden (steps / day; rs=20.49; 95% CI 20.33, 20.63, P,0.01). There were no systematic differences in physical activity
between different genotypes mitochondrial disease.
Conclusions: These results demonstrate for the first time that low levels of physical activity are prominent in mitochondrial
disease. Combined with a high prevalence of obesity, physical activity may constitute a significant and potentially
modifiable risk factor in mitochondrial disease.
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Introduction
Mitochondria are ubiquitous intracellular organelles found in all
nucleated cells and are responsible for energy production and
cellular respiration. They are involved in various different cellular
processes including calcium signalling [1], cellular metabolism [2],
and cytochrome c mediated apoptosis [3]. Mitochondrial enzymes
are integral in intermediary metabolism [4]; but, it is usually
defects in the respiratory chain, the common final pathway of
energy metabolism that result in what are termed mitochondrial
cytopathies [5]. Mitochondrial disorders typically affect organs
that are heavily dependent on oxidative metabolism such as the
brain, eye and skeletal muscle and consequently are commonly
characterised by multi-system involvement and variable pheno-
typic expression, disease severity and rate of progression [6,7,8].
Mitochondrial disease is the most common neuromuscular disease
[9] and there are currently no validated therapies.
Exercise intolerance is a characteristic hallmark of patients with
mitochondrial disease, with muscle weakness and fatigue reported
after low levels of exertion [10]. It is not known whether the
reduced exercise tolerance associated with mitochondrial disease is
associated with reduced daily physical activity. As an important
mediator of mortality, life expectancy, physical function and the
onset of disability in normal aging [11,12,13], physical activity
may represent an environmental influence that acts independently
of the genetic predisposition.
Several studies have now shown that the reversal of a sedentary
lifestyle in mitochondrial disease with exercise therapy confers
benefits to mitochondrial function and have confirmed safety
[14,15,16,17]. Before critically evaluating exercise as a potential
therapy in mitochondrial disease it is important to understand the
additional risks that patients with mitochondrial disease may be
exposed to as a result of low levels of habitual physical activity.
Consequently, the aims of this study were to characterise habitual
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evaluate its relationship with genotype and phenotype.
Methods
Subjects
One hundred patients with a diagnosis of mitochondrial disease
were enrolled in the study. Forty-seven participants had a
diagnosed point mutation (29 patients with m.3243A.G MELAS
mutation; 8 patients with m.8344A.G MERRF mutation: 9
patients with other mitochondrial tRNA (mt-tRNA) mutations).
Twenty-eight participants were diagnosed with multiple mtDNA
deletions (15 patients unspecified nuclear genetic defect, three
patients OPA1 (optic atrophy type 1), five patients POLG1
(polymerase gamma) and five patients PEO1 (Twinkle)). Twenty-
one participants were diagnosed with heteroplasmic single-large
scale mtDNA deletion. The remaining four patients had
uncharacterised genetic defects, but presence of ragged red fibres
and Cox negative staining from their biopsy (1–3%). From the
patient group 1 participant was wheelchair bound and 1 used a
wheel chair for mobilization outside the home. None of the
patients were taking part in any exercise based interventions
during the duration of the trial. Two of the patients had clinically
identified mild cardiomyopathy but without exercise limitation,
none had undergone formal evaluation of liver function. All
patients had cognitive function sufficient for provision of informed
consent (Mini-Mental State Examination .26). The control group
consisted of 100 participants, individually matched by age, gender
and body mass index (BMI). Participants were over 18 years of age
and gave written informed consent. All participants provided
informed consent and the study was approved by the Newcastle
regional medical research ethics committee.
Physical Activity
Habitual physical activity was measured objectively using a
validated multi-sensor array [18] (SenseWear Pro3, Bodymedia
Inc, PA, USA) worn over 3 days. Physical activity data are
presented as average METs / day, where 1 MET = resting
metabolic rate, or in steps / day. Patterns of sedentary behaviour
were assessed by power law analyses of the lengths of sedentary
bouts fitted from raw sedentary data, as described in more detail
previously [19]. Briefly; the density p(x) of sedentary bouts in a time
bin width d(x) was plotted against the bout length x on a
logarithmic scale to derive power distribution (equation 1) from
the shape of the histogram with respect to there length a:
p(x)~CX{a ð1Þ
The type of sedentary distribution characterised by the
exponent a (equation 2), can quantify different sedentary
behaviour strategies, with a lower a indicating that subjects
accumulate sedentary time with a larger proportion of long
sedentary bouts:
a~1z
X n
i~1
ln
xi
xmin
"# {1
ð2Þ
From these power distributions, Lorentz curves were calculated
where the fraction Wx of the total sedentary time that is
accumulated in bouts longer than any sedentary period of length x:
Wx~
ð?
x
x,p(x,)dx,
ð?
xmin
x,p(x,)dx,
ð3Þ
The curves are then plotted as Wx / p(x) pairs for each patient and
control. Activity patterns were also assessed by assessing transitions
from being inactive to active and normalized by the length of the
recording, termed ‘‘Sedentary to Active Transitions’’. These data are
presented as a percentage of the activity data per day. Subjective
reports of habitual physical activity were assessed using the
International Physical Activity Questionnaire (IPAQ) long form [20].
Clinical Presentations
Disease severity was assessed using the Newcastle Mitochondrial
Disability Adult Scale (NMDAS) [21]. The NMDAS is a validated
clinical rating scale consists of four domains: current function;
system specific involvement; current clinical assessment; and quality
of life. Each item within these domains is allocated one question
with a six-point response scale scored between 0 (unaffected) and
5(severely affected). A low NMDAS score is advantageous and a
high NMDAS score is disadvantageous for the patient. This tool
semi-quantifies disease severity and longitudinally, can evaluate the
long-term natural progression of mitochondrial myopathies.
Statistical Analysis
AssessmentofnormalitywasperformedusingaShapiroWilksTest
and skewed data were transformed using natural logarithms or
analysed using rank tests. Differences between patient and control
group values were calculated and analysed using paired t-tests. The
relationships between physical activity and clinical presentations in
the patient group were determined using hierarchical regression,
controlling for age, gender and BMI. Relationships between physical
activity and BMI in patient and control groups were also determined
using regression models, adjusted for age, gender and, where
appropriate, disease severity. Variables included in the NMDAS
were assessed using correlation and regression techniques to
determine their relative contribution to the relationship between
physical activity and disease severity. Assumption and diagnostic
checks were performed on all data. All statistical analyses were
performed using SPSS for Windows, version 16 (SPSS Inc., Illinois,
USA).Allvaluesareexpressedasmean6SD unless otherwise stated.
Results
Baseline characteristics
Generalgroup descriptions stratified by genotype can be found in
Table 1. Habitual physical activity was low, with 78% of the patient
cohort taking less than 10,000 steps per day. Twenty-eight per cent
of the mitochondrial disease group were overweight (BMI 25–
29.9 kg/m
2) and 20% were obese (BMI $30 kg/m
2); only 4% were
underweight (BMI,18.5 kg/m
2). Patient characteristics (gender,
age, BMI, number of steps walked per day, average METS and
NMDAS score) were similar across genotype categories.
Age, gender, disease burden and physical activity
Mitochondrial disease patients performed significantly less
physical activity than the control group (Table 1), with mean
differences between groups of 3041 steps per day (95% CI 1966,
4117) and 0.09 average METs per day (95% CI 0.02, 0.16). A
higher disease burden assessed by the NMDAS was associated
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rs=20.49; 95% CI 20.33, 20.63, P,0.01, avMETs / day;
rs=20.30; 95% CI 20.11, 20.47, p,0.01). After partitioning the
variance accounted for by age, gender and BMI, the variance in
physical activity (METs and steps, respectively) explained by
disease severity was 4 – 15%.
The NMDAS subscales showing significant correlations with
physical activity variables were entered into exploratory regression
models; the only variable to be retained in all models following
stepwise iterations was the exercise subscale, with R
2 values of 25%
when steps per day was the response variable and 19% for METs.
Physical activity as measured by METs was negatively associated
with BMI in both patient and control groups, with a stronger
relationship evident in the control group. In the patient group,
METswasa significantpredictor(b=20.32,p=0.002)ofBMIand
accounted for 10.3% of the variance after partialling out the effects
of age, gender and disease severity. After adjusting for age and
gender, METs was a significant predictor (b=20.67, p,0.001) of,
and accounted for 34.8% of the variance in, BMI in the control
group. Physical activity as measured by steps per day was not a
significant predictor of BMI in either patient or control groups.
Low levels of physical activity were common in the patient
group, with half of the group having an average daily energy
expenditure of less than 1.4 times their resting metabolic rate.
Objective measures of physical activity were seen to be moderately
associated with subjective reports of physical activity at work,
leisure time, active transport (steps variable only) and with the
amount of time (min) spent sitting per day (0.25,rs,0.35; lowest
95% confidence limit 0.05, highest 0.51). Objective measures of
physical activity were not associated with subjective reports during
domestic & gardening activities.
Sedentary Activity
Power law analyses of the lengths of sedentary bouts
demonstrate that patients with mitochondrial disease have a
longer duration of sedentary bout (Figure 2A, Mean difference
0.02; 95% CI 0.01, 0.03, t74=3.32, p=0.001). The number of
transitions from being sedentary to activity were significantly lower
in patients with mitochondrial disease compared with controls
(Figure 2B, Mean difference 20.01; 95% CI 20.02, 20.00,
t75=22.78, p=0.007).
Discussion
This is the first study to report daily physical activity levels of
people with mitochondrial disease. The major findings of this study
are: 1) a sedentary lifestyle is prominent in people with
mitochondrial disease, 2) across all genotypes there is a significant
inverse relationshipbetweenclinical rating andmeasures of physical
activity, with patients with greater phenotypic disease burden
undertaking less daily physical activity; and 3) 48% of the patient
group were either overweight or obese; only 4% were underweight.
The first key observation was the low level of physical activity in
the patient cohort; with 78% of the patients not achieving
internationally advised levels of physical activity (10,000 steps per
day [22]). The failure to achieve advised levels of physical activity
is acknowledged to have an adverse influence upon healthy living,
compounding metabolic diseases and reducing life expectancy
[12,23,24]. Recent studies have suggested that sedentary behav-
iour, in contrast to active energy expenditure, is possibly a more
important predictor of metabolic risk though its significant impact
on metabolic regulation [24,25]. In this light, analysis of the raw
physical activity data reveals that the average duration of
sedentary periods is longer in patients with mitochondrial disease
than controls. Breaks in sedentary time are also fewer than
controls. Combined, these data suggest that patients with
mitochondrial disease are at an increased risk of metabolic disease
due to their low levels of physical activity and prominent sedentary
behaviour, independent of their genetic predisposition.
Clinical rating was inversely related to habitual physical activity,
with those undertaking less physical activity having greater
physical impairment. The relationship between clinical rating
and habitual physical activity is intuitive and follows similar
relationships demonstrated in other metabolic disorders [24]. The
large variation in physical activity data for people with similar
disease burden also provides an insight into the ability of people
with mitochondrial disease to maintain a physically active lifestyle.
There are individuals with low clinical ratings (,4) who have no
clinical reason to have low levels of physical activity, yet have very
low levels of habitual physical activity (,2000 steps per day /
,1.3 METS/day [Figure 1]). Conversely, there are those with
high clinical ratings who do have significant physical impairment,
yet achieve high levels of physical activity. As such, although
clinical phenotype is broadly related to physical activity it is clear
that clinical phenotype alone does not dictate the level of physical
activity. This observation is of particular interest as several studies
have now shown that the reversal of a sedentary lifestyle with
exercise therapy confers benefits to mitochondrial function and
have confirmed safety [14,15,16,17].
Additional information can be gleaned by analysis of the sub-
scales of the NMDAS and the subjective reports of physical
activity. Clinical sub-scales associated with physical function, such
Table 1. Clinical, physical, and descriptors of habitual physical activity for all study participants and for subgroups by genetic
mutation.
Genotype N Age BMI
Clinical Rating
(NMDAS)
Average Daily
METS
Number of Steps
Walked Per Day
Subjective recall of
Physical activity
(met.min.wk)
Point Mutations 47 47612 25662 1 614 1.460.3 696763760 234465253
Multiple Deletions 28 56611 27652 8 616 1.460.3 716264187 341461466
Single deletion 21 49613 25652 3 615 1.360.2 636063745 212562347
Complex deficiency 4 51614 23642 0 624 1.460.4 671567055 549465385
All patients 100 50612 26672 3 615 1.460.3* 688363944* 335665531
Control group 100 50613 2564 - 1.560.2 992464088 -
Data are expressed as Mean 6 SD. * = significantly different from control group.
doi:10.1371/journal.pone.0022294.t001
Physical Activity and Mitochondrial Disease
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22294as cerebellar dysfunction and exercise intolerance were associated
with low levels of physical activity. Again, there is significant
breadth in the clinical presentations within these scales – with
some phenotypically healthy individuals demonstrating low levels
of physical activity and vice versa. There was no association
between habitual physical activity and the subscales of myopathy
or neuropathy as may have been expected. This may in part be
due to the mild nature of both parameters in this cohort. These
observations suggest that disease burden is a strong predictor of
habitual physical activity but is not the only determinant.
Subjective reports of physical activity provide information about
where in everyday life people are physically active and where
Figure 1. Scatter plot of the relationship between disease burden (total NMDAS score) and habitual physical activity (steps walked
per day) (unadjusted regression line, R-Sq=0.22, p,0.001). The red zone represents under and green zone over 10,000steps per day; the
advised level of physical activity by the World Health Organisation [22] for health.
doi:10.1371/journal.pone.0022294.g001
Figure 2. Power law analyses of the lengths of sedentary bouts of patients with mitochondrial disease [line] and controls [dashed]
(Panel A). Sedentary to Active Transitions, indicating transition from inactive to active periods, in patients with mitochondrial disease [grey] and
controls [open] (Panel B). Data are Mean 6 SD. * = significantly different from control p=0.007.
doi:10.1371/journal.pone.0022294.g002
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leisure time physical activities were a key determinant of overall
physical activity. Not surprisingly, low levels of daily physical
activity are associated with high levels of sitting. These
observations suggest that some of the key clinical presentations
are associated with physical activity and that physical activity, in
turn, is reduced in parts of the day where the patients’ave choice of
movement, that is, work, leisure an d sitting. The high level of
sitting time associated with mitochondrial disease is particularly of
concern as high levels of sitting time are associated with a 2.5 times
greater risk of heart disease and the development of metabolic
syndrome [12,24]. The next challenge is to better understand how
these areas of life can be targeted to increase physical activity, with
a view to improving clinical features and reducing metabolic
disease risk.
Almost half of the patients were overweight and one in five
classified as obese [22]. This is contrary to historical descriptions of
svelte body habitus of mitochondrial disease, particularly in
relation to the 3243 A.G genotype [26]. This would suggest that
people with mitochondrial disease are at added risk of high
morbidity and mortality as posed by obesity and low physical
activity in addition to the inherent predispositions that accompany
mitochondrial disease.
These results show that the majority of people with mitochon-
drial disease lead an essentially sedentary lifestyle and that low
levels of physical activity are related to clinical correlates of
function and obesity. Combined, these observations suggest that
low levels of physical activity, alongside a high prevalence of
obesity, constitute significant disease risk factors in addition to the
inherent predispositions that accompany mitochondrial disease
and may represent a significant therapeutic target.
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